{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"46.8","value":"40.8"},{"groupId":"OG001","lowerLimit":"31.6","upperLimit":"43.1","value":"37.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"285"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants whose best overall response was either complete response (CR) or partial response (PR) according to RECIST version 1.0. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"OG000","title":"Everolimus + Vinorelbine + Trastuzumab"},{"description":"Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"OG001","title":"Placebo + Vinorelbine + Trastuzumab"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients.","reportingStatus":"POSTED","timeFrame":"Every 6 weeks until disease progression or death which ever occurred first up to about 41 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}